$5.54
10.36% today
Nasdaq, Apr 02, 09:20 pm CET
ISIN
US81734D1046
Symbol
SEPN
Sector
Industry

Septerna Stock price

$5.02
-1.04 17.16% 1M
-12.98 72.11% 6M
-17.88 78.08% YTD
-12.98 72.11% 1Y
-12.98 72.11% 3Y
-12.98 72.11% 5Y
-12.98 72.11% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
-0.77 13.30%
ISIN
US81734D1046
Symbol
SEPN
Sector
Industry

Key metrics

Market capitalization $223.10m
Enterprise Value $-102.34m
P/B ratio (TTM) P/B ratio 0.53
Cash position $350.92m
P/E forward negative
P/S forward 637.43
EV/Sales forward negative

Is Septerna a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Septerna Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Septerna forecast:

3x Buy
75%
1x Hold
25%

Analyst Opinions

4 Analysts have issued a Septerna forecast:

Buy
75%
Hold
25%

Financial data from Septerna

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
0.21 0.21
-
100%
- Direct Costs 0.39 0.39
-
186%
-0.18 -0.18
-
-86%
- Selling and Administrative Expenses 4.84 4.84
-
2,305%
- Research and Development Expense 19 19
-
9,200%
-24 -24
-
-11,586%
- Depreciation and Amortization 0.39 0.39
-
186%
EBIT (Operating Income) EBIT -25 -25
-
-11,771%
Net Profit -21 -21
-
-9,843%

In millions USD.

Don't miss a Thing! We will send you all news about Septerna directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Septerna Stock News

Positive
Seeking Alpha
2 days ago
Investing in biotech can be highly rewarding but is fraught with risks; understanding past catalysts can help investors make informed decisions and minimize downside risk. CervoMed Inc. surged over 300% in Q1 2025 due to positive Phase 2b trial results for its lead drug candidate, neflamapimod despite earlier setbacks. Chimerix Inc. gained over 144% after announcing an acquisition by Jazz Pharm...
Neutral
GlobeNewsWire
6 days ago
Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This Year Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for Mast Cell Diseases, Expected to Initiate in 2025 Well-Capitalized with $420.8M Balance Sheet as of YE 2024 to Support Operating Runway into Early 2028 SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GL...
Negative
24/7 Wall Street
28 days ago
Among the most notable insider purchases of the past week or so is an almost $20 million buy in an American semiconductor concern.
More Septerna News

Company Profile

Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. Its pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. The company was founded by Robert Joseph Lefkowitz, Arthur Christopoulos, Patrick Sexton, and Jeffrey T. Finer in December 2019 and is headquartered in South San Francisco, CA.

Head office United States
CEO Jeffrey Finer
Employees 75
Website www.septerna.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today